Pluristyx, a renowned cellular therapy developer, has partnered with Humacyte, a biotechnology company specializing in bioengineered human tissue. This collaboration will leverage Pluristyx’s advanced stem cell technology to create insulin-producing cells for Humacyte’s BioVascular Pancreas (BVP) therapy.

Pluristyx’s PluriBank™ stem cell line, renowned for its clinical-grade purity, genetic integrity, and safety features, will serve as the foundation for Humacyte’s efforts. Additionally, Pluristyx’s panCELLa™ platform enables the generation of “hypoimmune” cells, minimizing the risk of immune rejection after implantation.

Through this partnership, Pluristyx will provide access to their custom gene editing services, enhancing the BVP’s potential efficacy and safety. Dr. Benjamin Fryer, Pluristyx’s CEO, emphasized their commitment to supporting therapeutic developers in advancing cell-based therapies.

The BVP, engineered to revolutionize type 1 diabetes treatment, involves the delivery of insulin-producing islets within the body using Humacyte’s Acellular Tissue Engineered Vessel (ATEV™). The ATEV and BVP are currently investigational products awaiting regulatory approval.

Pluristyx’s panCELLa™ platform, combining cutting-edge iPSC technology and genetic engineering capabilities, empowers the development of innovative cell therapies. The company’s end-to-end support accelerates clinical trials and facilitates the commercialization of cell-based treatments.

Source link: http://www.businesswire.com/news/home/20240709531825/en/Pluristyx-Announces-License-Agreement-with-Humacyte-to-Develop-BioVascular-Pancreas-using-iPSCs

Jon Napitupulu
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.